ArticlePulmonary circulation2025
Chronic Thromboembolic Pulmonary Hypertension in Latvia: Epidemiological Insights and Diagnostic Challenges From 2024.
Article in Pulmonary circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Chronic Thromboembolic Pulmonary Hypertension in Latvia: Epidemiological Insights and Diagnostic Challenges From 2024.Pulmonary circulation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but serious disease caused by persistent thromboembolic obstruction or narrowing of the pulmonary arteries. Its prevalence varies, and many cases remain undiagnosed, contributing to a substantial clinical burden. This study aimed to summarize all CTEPH cases diagnosed in Latvia in 2024, calculate the annual incidence, and present additional epidemiological data from Latvian pulmonary hypertension (PH) registry. Additionally, we sought to document the presence of risk factors in individual patients and analyze their diagnostic pathways leading to a diagnosis of CTEPH. This observational study aimed to analyze diagnostic pathways and identify risk factors in all patients diagnosed with CTEPH in Latvia in 2024. Diagnosis was confirmed at Pauls Stradins Clinical University Hospital according to ESC guideline criteria. Patients completed the emPHasis-10 questionnaire and underwent a structured interview. In 2024, 15 patients were diagnosed with CTEPH in Latvia, corresponding to an annual incidence of 8.01 cases per million. Prevalence was 31.51 per million, and mortality-3.74 per 100 person-years. Patients diagnosed within 2 years of symptom onset had lower pulmonary vascular resistance compared to those diagnosed later. The most common risk factor was prior acute pulmonary embolism (80%). In 60% of cases, diagnosis was delayed by more than 2 years, reflecting late referral to a PH centre. CTEPH remains frequently misdiagnosed and undertreated. Improved recognition of risk factors and stronger collaboration with specialized PH centres are essential to optimize patient management and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.